Paper42224880
Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application.
Khan RMN and 8 others. J Chromatogr B Analyt Technol Biomed Life Sci, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application. Papers, record 42224880. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42224880
- Disease
- Proteus syndrome1 drug
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Liquid Chromatography-Mass Spectrometry | Major topic |
| Tandem Mass Spectrometry | Major topic |
| Humans | |
| Chromatography, Liquid | |
| Drug Stability | |
| Limit of Detection | |
| Linear Models | |
| Reproducibility of Results | |
| Aminopyridines | |
| Imidazoles |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIA CL090115 | Intramural NIH HHS | United States | ZIACL090115 | PubMed |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04316546 | MK-7075 (Miransertib) in Proteus Syndrome | Derived from the trial | Yes |
Source ClinicalTrials.gov
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27305487 | Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. | J Med Chem | 2016 | https://conductscience.org/library/papers/27305487 | PubMed |
| 2 | 20056435 | Association of paternal age and risk for major congenital anomalies from the National Birth Defects Prevention Study, 1997 to 2004. | Ann Epidemiol | 2010 | https://conductscience.org/library/papers/20056435 | PubMed |
| 3 | 29240615 | Enhancement and Suppression of Ionization in Drug Analysis Using HPLC-MS/MS in Support of Therapeutic Drug Monitoring: A Review of Current Knowledge of Its Minimization and Assessment. | Ther Drug Monit | 2018 | https://conductscience.org/library/papers/29240615 | PubMed |
| 4 | 32014856 | Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). | Cold Spring Harb Mol Case Stud | 2020 | https://conductscience.org/library/papers/32014856 | PubMed |
| 5 | 31058421 | First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. | Am J Med Genet A | 2019 | https://conductscience.org/library/papers/31058421 | PubMed |
| 6 | 26657992 | Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome. | Sci Rep | 2015 | https://conductscience.org/library/papers/26657992 | PubMed |
| 7 | 33639990 | Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome. | Orphanet J Rare Dis | 2021 | https://conductscience.org/library/papers/33639990 | PubMed |
| 8 | 21793738 | A mosaic activating mutation in AKT1 associated with the Proteus syndrome. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21793738 | PubMed |
| 9 | 39353238 | The evolution of small-molecule Akt inhibitors from hit to clinical candidate. | Eur J Med Chem | 2024 | https://conductscience.org/library/papers/39353238 | PubMed |
| 10 | 20886116 | Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. | PLoS One | 2010 | https://conductscience.org/library/papers/20886116 | PubMed |
| 11 | 12964746 | Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. | Anal Chem | 2003 | https://conductscience.org/library/papers/12964746 | PubMed |
| 12 | 34858045 | Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. | Pharmgenomics Pers Med | 2021 | https://conductscience.org/library/papers/34858045 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| AKT2 | 208 | PubTator's text mining | https://conductscience.org/library/genes/208 | NCBI Gene |
| AKT3 | 10000 | PubTator's text mining | https://conductscience.org/library/genes/10000 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| MIRANSERTIB | CHEMBL4297188 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4297188 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Cited by
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42224880
GET https://conductscience.org/api/papers/v1/42224880/authors